News

Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.

The product, which is used to increase female sexual arousal and desire and satisfaction, is approved for marketing in alternative markets which excludes all medical and mainstream sales

The company has already completed the pre-launch preparation of the generic drug and will now be entitled to 180 days of marketing exclusivity under Hatch Waxman rules. According

Currently, PF-06425090 is in Phase II clinical development and it is designed to prevent C. difficile-associated disease, which can include life-threatening diarrhea and pseudomembranous colitis. FDA fast track

The NIH’s $150,000 grant will support the continued preclinical research collaboration between the company and the California Institute for Medical Research (CIMR), which is focused on creating the

The NDA is based on global clinical trial results from the large, multi-center, randomized, double-blind, placebo-controlled, outcomes Phase III Systolic Heart failure treatment with the If inhibitor ivabradine

The new facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD. EMD Millipore president and

This is its fourth dedicated research centre in South Africa and brings Synexus global site count to 24 with 3 new centres being opened in the last six

The ‘829 patent application includes newly allowed claims directed to compositions comprising a double-stranded molecule of between 19 and 52 nucleotides in each strand with various end configurations,